Everolimus-induced lymphedema in a renal transplant recipient: A case report

Experimental and Clinical Transplantation

Volumn 10, Issue 3, 2012, Pages 296-298

  Ersoy, Alparslan ^a   Koca, Nizameddin ^b  

^a ULUDAG UNIVERSITY   (Turkey)

^b Department of Internal Medicine ^*  (Turkey)

Author keywords

Complication; Edema; Immunosuppression; Kidney transplant; mTOR inhibitors

Indexed keywords

BASILIXIMAB; CREATININE; CYCLOSPORIN; EVEROLIMUS; GLUCOSE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; FEMALE; FOOT EDEMA; GRAFT RECIPIENT; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYMPHEDEMA; LYMPHOSCINTIGRAPHY; POSTOPERATIVE CARE; THROMBOCYTOPENIA;

FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LYMPHEDEMA; LYMPHOSCINTIGRAPHY; MIDDLE AGED; SIROLIMUS; TIME FACTORS; TRANSPLANTATION; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84862630478     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: 10.6002/ect.2011.0139     Document Type: Article

References (11)

1. Rostaing L, Kamar N. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol. 2010;23(2):133-142.
2. Romagnoli J, Citterio F, Nanni G, Tondolo V, Castagneto M. Severe limb lymphedema in sirolimus-treated patients. Transplant Proc. 2005;37(2):834-836.
3. Al-Otaibi T, Ahamed N, Nampoory MR, et al. Lymphedema: an unusual complication of sirolimus therapy. Transplant Proc. 2007;39(4):1207-1210.
4. Rico J, Cruzado JM, Bestard O, et al. Subclinical rejection and sirolimus associated edema in renal allograft recipients. Transpl Int. 2007;20(7):636-639.
5. De Bartolomeis C, Collini A, Rumberger B, et al. Generalized lymphedema in a sirolimus-treated renal transplant patient. Clin Transplant. 2008;22(2):254-257.
6. Fuchs U, Zittermann A, Berthold HK, et al. Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema. Transplantation. 2005;79(8):981-983.
7. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8(2):128-135.
8. Guba M, Yezhelyev M, Eichhorn ME, et al. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood. 2005;105(11):4463-4469.
9. Karkkainen MJ, Ferrell RE, Lawrence EC, et al. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet. 2000;25(2):153-159.
10. Mäkinen T, Jussila L, Veikkola T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med. 2001;7(2):199-205.
11. Huber S, Bruns CJ, Schmid G, et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int. 2007;71(8):771-777.